AAH Pharmaceuticals

DGAP-News: AURELIUS Equity Opportunities reports robust growth also in the first half of 2022 despite persistently tough economic conditions

Retrieved on: 
Thursday, August 11, 2022
John Bell & Croyden, Exercise, VAG, CEO, Container, Sport, ISIN, Sale, ESG, EBITDA, McKesson Corporation, Building material, Mission statement, NAV, Acquisition, An de Ryck, LloydsPharmacy, NDS, Final good, Saint-Gobain, JD Sports, RTS, Orica, Goal, BMC, AAH Pharmaceuticals, Minova, Industrial production, Security (finance), Renewable energy, Bank, Financial services, Retail, Group

The first half of 2022 was marked by extraordinary and persistent macroeconomic challenges.

Key Points: 
  • The first half of 2022 was marked by extraordinary and persistent macroeconomic challenges.
  • Despite persistent challenges in the market, AURELIUS Equity Opportunities sharpened the focus of its portfolio further in the first half of 2022.
  • The co-investment structure, operating jointly with AURELIUS European Opportunities Fund IV, made three new acquisitions in the first half of the year.
  • The AURELIUS Equity Opportunities Group expects a consistently constructive transaction environment in the second half of 2022.

DGAP-News: AURELIUS Equity Opportunities begins the 2022 financial year with a robust first quarter

Retrieved on: 
Thursday, May 12, 2022
ESG, History, Partners Group, EBITDA, VAG, ISIN, Share repurchase, BGP, Industrial production, AAH Pharmaceuticals, RTS, McKesson Corporation, Orica, NAV, Mining, CTD, Final good, Saint-Gobain, LloydsPharmacy, United Nations Global Compact, Sale, B2B, Container, BMC, Acquisition, John Bell & Croyden, Minova, CEO, Security (finance), Film, Financial services, Renewable energy, Risk management, EUR, Group

The first quarter of 2022 was characterized by a high level of transaction activity on the part of AURELIUS Equity Opportunities.

Key Points: 
  • The first quarter of 2022 was characterized by a high level of transaction activity on the part of AURELIUS Equity Opportunities.
  • Acting together with AURELIUS European Opportunities Fund IV, AURELIUS Equity Opportunities also expanded the jointly held portfolio through additional acquisitions.
  • Moreover, an additional analyst firm, Pareto Securities, has commenced coverage of AURELIUS Equity Opportunities with a buy recommendation.
  • AURELIUS Equity Opportunities will hold its 2022 annual general meeting on June 21, 2022.

DGAP-News: AURELIUS completes acquisition of LloydsPharmacy's parent company, McKesson UK

Retrieved on: 
Tuesday, April 12, 2022
Cardano, LloydsPharmacy, Aurelius Group, Life, Pharmacy, FRP, AEO, DLA, John Bell & Croyden, Rothschild, McKesson Corporation, Pension, Texas Homecare, Commercial, PricewaterhouseCoopers, Refugee, AAH Pharmaceuticals, Embassy of Luxembourg, London, Digital, Acquisition, Patient, Corporate finance, Commercial property, Security (finance), Financial services

AURELIUS completes acquisition of LloydsPharmacy's parent company, McKesson UK

Key Points: 
  • AURELIUS completes acquisition of LloydsPharmacy's parent company, McKesson UK
    The issuer is solely responsible for the content of this announcement.
  • AURELIUS completes acquisition of LloydsPharmacy's parent company, McKesson UK
    Luxembourg/London, April 07, 2022 - AURELIUS is pleased to announce that it has successfully closed the acquisition of McKesson UK.
  • McKesson UK is the parent company of a number of market leading healthcare businesses including LloydsPharmacy, John Bell & Croyden and AAH Pharmaceuticals.
  • AURELIUS will ensure a smooth transition as McKesson UK separates from its former US-based parent company, McKesson Corporation.

DGAP-News: In its biggest deal in history, AURELIUS acquires McKesson UK

Retrieved on: 
Monday, November 1, 2021
Cardano, EBITDA, PricewaterhouseCoopers, Rothschild, McKesson Corporation, ISIN, Texas Homecare, History, Patient, Pharmacist, Corporate finance, AEO, SSE plc, Refugee, DLA, Life, Pension, Investment, LloydsPharmacy, GBP, Acquisition, Aurelius Group, Nursing, Commercial, Ownership, AAH Pharmaceuticals, Digital, FRP, Telecommunication, Security (finance), Retail, Financial services

In its biggest deal in history, AURELIUS acquires McKesson UK

Key Points: 
  • In its biggest deal in history, AURELIUS acquires McKesson UK
    The issuer is solely responsible for the content of this announcement.
  • In its biggest deal in history, AURELIUS acquires McKesson UK
    - AURELIUS agrees to acquire McKesson UK, the UK's leading fully integrated healthcare provider, across retail, wholesale, homecare and digital platforms for an enterprise value of GBP 477m
    - Co-investment structure together with AURELIUS Equity Opportunities SE & Co. KGaA is already paying off
    Munich/London, November 1, 2021 - In its largest deal to date, AURELIUS today announces the acquisition of McKesson UK in a corporate carve-out from US healthcare company McKesson Corporation, Irving, Texas.
  • Our agreement with McKesson builds on AURELIUS' proven track record as a trusted investor in corporate carve-outs, leveraging AURELIUS' operational expertise to grow portfolio companies.
  • With its group charity AURELIUS Refugee Initiative e.V., AURELIUS provides comprehensive support for refugees on their way towards a better life.

McKesson Corporation Enters Agreement to Sell UK Businesses to AURELIUS

Retrieved on: 
Monday, November 1, 2021
Pharmaceutical, Health, Medical Supplies, Medical Devices, Online, Pharmacy, FORTUNE, Securities Act of 1933, McKesson Corporation, COVID-19 vaccine, Organization, Security (finance), U.S. Securities and Exchange Commission, Patient, NYSE, Echo, NHS, Investment, Human Rights Campaign, LloydsPharmacy, COVID-19, Growth, Form 10-K, Lists of disasters, Health, Drug Quality and Security Act, Risk, AAH Pharmaceuticals, Sale, Securities Exchange Act of 1934, MCK, Pharmaceutical industry

McKesson Corporation (NYSE: MCK) today announced that it has entered into an agreement to sell its UK businesses to AURELIUS, a pan-European asset management group with offices in Munich, London, Stockholm, Madrid, Amsterdam, Milan and Luxembourg.

Key Points: 
  • McKesson Corporation (NYSE: MCK) today announced that it has entered into an agreement to sell its UK businesses to AURELIUS, a pan-European asset management group with offices in Munich, London, Stockholm, Madrid, Amsterdam, Milan and Luxembourg.
  • The transaction includes the sale of McKesson UK businesses LloydsPharmacy, LloydsDirect (previously Echo by LloydsPharmacy), AAH Pharmaceuticals, LloydsPharmacy Clinical Homecare, LloydsPharmacy Online Doctor, MASTA and John Bell & Croyden.
  • AURELIUS expects to support McKesson UK by further investing in and growing each of its business divisions.
  • McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions.